Skip to content

Released Jan 30, 2024, before the open

10-K filed Feb 22, 2024, 53 days after period end · 0000078003-24-000039

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$5.93Bderived−62.4% vs Q4 2022−56.0% vs Q3 2023
Net Income-$3.37BderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived$5,240,000,000−38.9%
Free Cash Flowderived$4,196,000,000−44.7%
Margins · derived
Net margin-56.8%−88.5 pt vs Q4 2022

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figures
Revenue$5.93B$15.75B$16.19B$11.43B
Net Income-$3.37B$4.99B$3.39B$846.00M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR